Hy's law: Difference between revisions

	WikiDoc Resources for Hy's law
Articles
Most recent articles on Hy's law Most cited articles on Hy's law Review articles on Hy's law Articles on Hy's law in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Hy's law Images of Hy's law Photos of Hy's law Podcasts & MP3s on Hy's law Videos on Hy's law
Evidence Based Medicine
Cochrane Collaboration on Hy's law Bandolier on Hy's law TRIP on Hy's law
Clinical Trials
Ongoing Trials on Hy's law at Clinical Trials.gov Trial results on Hy's law Clinical Trials on Hy's law at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Hy's law NICE Guidance on Hy's law NHS PRODIGY Guidance FDA on Hy's law CDC on Hy's law
Books
Books on Hy's law
News
Hy's law in the news Be alerted to news on Hy's law News trends on Hy's law
Commentary
Blogs on Hy's law
Definitions
Definitions of Hy's law
Patient Resources / Community
Patient resources on Hy's law Discussion groups on Hy's law Patient Handouts on Hy's law Directions to Hospitals Treating Hy's law Risk calculators and risk factors for Hy's law
Healthcare Provider Resources
Symptoms of Hy's law Causes & Risk Factors for Hy's law Diagnostic studies for Hy's law Treatment of Hy's law
Continuing Medical Education (CME)
CME Programs on Hy's law
International
Hy's law en Espanol Hy's law en Francais
Business
Hy's law in the Marketplace Patents on Hy's law
Experimental / Informatics
List of terms related to Hy's law

VisualWikitext

Revision as of 18:21, 21 April 2010

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Hy's law is defined as drug-induced liver injury (DILI) leading to jaundice. The law is based on observations by Hy Zimmerman, a major scholar of drug-induced liver injury. ^[1]^[2]

Definition

Hy’s Law cases have the following three components (http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0396-gdl0001.pdf):

The drug causes hepatocellular injury, generally shown by more frequent 3-fold or greater elevations above the ULN of ALT or AST than the (nonhepatotoxic) control agent or placebo.
Among subjects showing such AT elevations, often with ATs much greater than 3xULN, some subjects also show elevation of serum TBL to >2xULN, without initial findings of cholestasis (serum alkaline phosphatase (ALP) activity >2xULN).
No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C, preexisting or acute liver disease, or another drug capable of causing the observed injury.

Prognosis

Without a hepatic transplant, patients meeting criteria for Hy's Law face a case fatality rate of 10% to 50%.

References

Template:WH Template:WikiDoc Sources

[1] .gov

[2] FDA draft guidance on drug-induced liver injury, Oct 2007

[1]

[2]

@@ Line 5: / Line 5: @@
 {{EH}}
-'''Hy's law''' is a [[Prognosis|prognostic indicator]] that a pure [[hepatotoxicity|drug-induced liver injury]] (DILI) leading to [[jaundice]], without a [[liver transplantation|hepatic transplant]], has a case fatality rate of 10% to 50%. The law is based on observations by [[Hy Zimmerman]], a major scholar of drug-induced liver injury.
+===Overview===
+'''Hy's law''' is defined as [[hepatotoxicity|drug-induced liver injury]] (DILI) leading to [[jaundice]]. The law is based on observations by [[Hy Zimmerman]], a major scholar of drug-induced liver injury.  <ref>[http://www.fda.gov/CDER/GUIDANCE/3580fnl.htm fda.gov]</ref><ref>[http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0396-gdl0001.pdf FDA draft guidance on drug-induced liver injury, Oct 2007]</ref>
+===Definition===
 Hy’s Law cases have the following three components (http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0396-gdl0001.pdf):
 #The drug causes hepatocellular injury, generally shown by more frequent 3-fold or greater elevations above the ULN of ALT or AST than the (nonhepatotoxic) control agent or placebo.
 #Among subjects showing such AT elevations, often with ATs much greater than 3xULN, some subjects also show elevation of serum TBL to >2xULN, without initial findings of cholestasis (serum alkaline phosphatase (ALP) activity >2xULN).
-#No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C, preexisting or acute liver disease, or another drug capable of causing the observed injury.   <ref>[http://www.fda.gov/CDER/GUIDANCE/3580fnl.htm fda.gov]</ref><ref>[http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0396-gdl0001.pdf FDA draft guidance on drug-induced liver injury, Oct 2007]</ref>
+#No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C, preexisting or acute liver disease, or another drug capable of causing the observed injury.
+==Prognosis==
+Without a [[liver transplantation|hepatic transplant]], patients meeting criteria for Hy's Law face a case fatality rate of 10% to 50%.
 ==References==
@@ Line 16: / Line 21: @@
 [[Category:Pharmacology]]
+[[Category:Clinical trials]]
+[[Category:Hepatology]]
+{{WH}}
 {{WikiDoc Sources}}